<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03955705</url>
  </required_header>
  <id_info>
    <org_study_id>Si204/2019</org_study_id>
    <nct_id>NCT03955705</nct_id>
  </id_info>
  <brief_title>Analgesic Effectiveness of Nefopam in Patients Undergoing Anterior Cervical Spine Surgery</brief_title>
  <official_title>Analgesic Effectiveness of Nefopam in Patients Undergoing Anterior Cervical Spine Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nefopam is a benzoxazocine derivative which is non-opioid and non NSAIDs. The previous
      studies showed that nefopam can inhibit reuptake of serotonin, norepinephrine and dopamine.
      It has no respiratory depression so may be useful in potential airway compromized surgery
      like anterior cervical discectomy and fusion (ACDF). This study aims to study the analgesic
      properties of nefopam after ACDF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators enroll 50 patient who admitted for ACDF. Standard general anesthesia will
      be performed in all of the patients. Then, an hour before finishing operation, the patients
      will be divided into two groups. The first group will receive Nefopam 20 mg infuse for 60
      min. The another group or group NSS will receive the same amount of 0.9% sodium chloride. The
      recorded data include patient demographic data, intraoperative blood loss, hemodynamics and
      pre and postoperative pain scores and Thai version of the Neuropathic Pain Symptom Inventory
      (NPSI-T score).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2019</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total morphine consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Intravenous morphine was given to all by patient controlled analgesia (PCA) machine. The higher morphine consumption reflects higher postoperative pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in Thai version of the Neuropathic Pain Symptom Inventory (NPSI-T score)</measure>
    <time_frame>30 days</time_frame>
    <description>Changes in NPSI-T (minimum 0- maximum 100) period by recording NPSI-T at preoperative period, compared with postoperative day 1, 3, 15,30. The total score is 100, the higher scores reflect higher neuropathic pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in pain scores</measure>
    <time_frame>72 hours</time_frame>
    <description>Changes in pain scores (minimum 0- maximum 10) at different time point 0 (upon arrival to recovery room), postoperative at 4, 8, 12, 16, 24, 48, 72 hours. The higher scores reflect higher pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cervical Spine Degeneration</condition>
  <arm_group>
    <arm_group_label>Nefopam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nefopam: 20 mg (infuse at least 15 minutes) every 4-6 hours, max 120 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline or 0.9% NaCl or NSS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nefopam 20 mg/ml</intervention_name>
    <description>Nefopam is a benzoxazocine derivative which is non-opioid and non NSAIDs. The previous studies showed that nefopam can inhibit reuptake of serotonin, norepinephrine and dopamine.</description>
    <arm_group_label>Nefopam</arm_group_label>
    <other_name>Acupan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>0.9% Sodium chloride (normal saline or NSS)</description>
    <arm_group_label>Normal saline solution</arm_group_label>
    <other_name>0.9% NaCl or NSS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with cervical spondylosis or cervical spondylotic myelopathy undergoing
             elective anterior cervical spine surgery such as ACDF or anterior cervical corpectomy
             and fusion (ACCF)

          -  ASA class I-III

          -  Age 18-75 years old

          -  Body weight &gt; 50 kg, BMI &lt; 30 kg/m2

        Exclusion Criteria:

          -  Convulsion or seizure

          -  Myocardial ischemia or infarction

          -  Risk of urinary retention from urethral disease or prostate disease

          -  Angle closure glaucoma

          -  Patients on monoamine oxidase inhibitor

          -  Psychiatric patients

          -  Pregnant or lactated woman

          -  Creatinine clearance &lt; 30 ml/min

          -  Allergic to nefopam

          -  Patients on pregabaline or gabapentin

          -  Poorly controlled hypertension

          -  Cannot understand or do the questionnaire of Thai version of Neuropathic pain symptom
             inventory (NPSI-T) score
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manee Raksakietisak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manee Raksakietisak, MD</last_name>
    <phone>+6624197990</phone>
    <email>simrs@mahidol.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chakkarin Homprasert, MD</last_name>
    <phone>+66846711413</phone>
    <email>c.homprasert@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of medicine, Siriraj hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Rao R. Neck pain, cervical radiculopathy, and cervical myelopathy: pathophysiology, natural history, and clinical evaluation. J Bone Joint Surg Am. 2002 Oct;84(10):1872-81. Review.</citation>
    <PMID>12377921</PMID>
  </reference>
  <reference>
    <citation>Dordoni PL, Della Ventura M, Stefanelli A, Iannace E, Paparella P, Rocca B, Accorra F. Effect of ketorolac, ketoprofen and nefopam on platelet function. Anaesthesia. 1994 Dec;49(12):1046-9.</citation>
    <PMID>7864317</PMID>
  </reference>
  <reference>
    <citation>Sunshine A, Laska E. Nefopam and morphine in man. Clin Pharmacol Ther. 1975 Nov;18(5 Pt 1):530-4.</citation>
    <PMID>1102231</PMID>
  </reference>
  <results_reference>
    <citation>Kim KH, Abdi S. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain. 2014 Apr;27(2):103-11. doi: 10.3344/kjp.2014.27.2.103. Epub 2014 Mar 28. Review.</citation>
    <PMID>24748937</PMID>
  </results_reference>
  <results_reference>
    <citation>Martinez V, Beloeil H, Marret E, Fletcher D, Ravaud P, Trinquart L. Non-opioid analgesics in adults after major surgery: systematic review with network meta-analysis of randomized trials. Br J Anaesth. 2017 Jan;118(1):22-31. doi: 10.1093/bja/aew391. Review.</citation>
    <PMID>28039239</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 7, 2019</study_first_submitted>
  <study_first_submitted_qc>May 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nefopam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

